#RNL2023 @RheumNow Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/WNqQ8HVP9n https://t.co/qWYLoMWELv

JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 ⁦@RheumNow⁩ https://t.co/72m0GnmBkZ https://t.co/IThonRjpWD

Korean retrospective claims analysis of #RA (n=54 .7K; 39K RF/CCP+) (2010-2019; F/U 4.3 yrs) saw Parkinsons dx in 290 RA; Compared to controls, RA had a significant 1.74-fold higher risk of PD (found in seropos HR 1.95) but not seroneg RA https://t.co/GRahCXDuYt https://t.co/ohWK51frFr

Treatment with MTX in early CCP+ RA thought to be effective in slowing disease however StopRA study did not show a difference between HCQ and PBO in patients. We need to know more about HCQ vs MTX in this space! #RNL2023 https://t.co/hkypaEwZ8F cc: @uptoTate https://t.co/hgZNyU8YwU

STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts @RheumNow #RNL2023 https://t.co/h1YicTORuw https://t.co/JRIFJzMudO

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/YrA7tXMKoI Cc: @ericdeinmd https://t.co/oXoeZYW7rU

#RNL2023 Kevin Deane: natural history of RA The onset of RA is a spectrum of disease from genetic/environmental risks; local & systemic autoimmunity (ACPA/RF, mucosal factors); subclinical; unclassified arthralgias; classified RA When to start treatment? https://t.co/LEsPVQe9QW https://t.co/MbNmxZ39HO

Retrospective study of Calif. Hosp. records on women with SLE (n 2874) and RA (2309) found that Black, Hispanic, and Asian women had 1.3 - 1.5 fold more preterm births than Whites; & blacks had 2-2.4 more PTB than Asian, Hispanic, or Whites. https://t.co/7Nr5KJUNRc https://t.co/3fzTMiM4DG

Swedish study looked at risk of PsA in psoriasis pts showing PsA risk was significantly higher w/ worsening psoriasis. Incidence of PsA was 1.48/100PY, 3.00, and 5.49/100PY w/ mild, moderate and severe psoriasis. PsA risk was 3.2X higher w/ severe PSO https://t.co/H8QbkRp4d9 https://t.co/Hqlcf3f2bI

Pharma marketing payments to MDs (none; < $100; >$100) correlated with Medicare billing of Intraarticular Hyaluronic Acid injx. In 20 501 MDs, 41.5% gave HA injx; Odds incr w/ payment <$100 (OR 2.06) or >$100 (OR 3.28); 12.7% & 21% more likely https://t.co/BP395xm0TW https://t.co/MDxT8Kl4kq

Observational study of cannabis use in 25 cancer pts (52% w/ colon/lung/breast CA) taking a 2-wks of ad libitum cannabis noted to have improvements in pain intensity, pain interference, sleep quality, & cognitive function,but no change in quality of life. https://t.co/iZjGMM1Pud https://t.co/vkOWVqfCYi